Jingfang Pharmaceutical-B (02595) had a total market capitalization of HK$912 million, accounting for 9.11%, transferred 245.884 million shares from China Securities Registration and Settlement Hong Kong

Zhitongcaijing · 3d ago

The Zhitong Finance App learned that the latest data from the Hong Kong Stock Exchange shows that on September 23, Jinfang Pharmaceutical-B (02595) changed positions, with a total transfer market value of HK$912 million, accounting for 9.11%. The company's shareholders transferred 8.782 million shares to China International Finance Hong Kong Securities and transferred 24.584 million shares from China Securities Registration and Settlement Hong Kong.

Jingfang Pharmaceutical-B issued an announcement. The board of directors of the company noticed a recent increase in the price of the company's shares and would like to inform the company's shareholders and potential investors about the latest business developments of the Group. The company's clinical project GFH375 combined with cetuximab was included in the Breakthrough Therapy (BTD) list by the Drug Evaluation Center of the State Drug Administration on September 18, 2026 to treat KRAS G12D mutant metastatic colorectal cancer that has previously failed chemotherapy based on oxaliplatin, fluorouracil, and irinotecan. The clinical project was applied for on August 13, 2026, and the publication deadline is September 24, 2026.

The company originally planned to announce the clinical project after it was officially included in the BTD list in accordance with market practice. However, in accordance with the relevant provisions of the “Listing Rules”, the review progress of this proposed inclusion in the BTD list will be announced at this stage. There is still a potential risk that the clinical project will not be approved after the announcement. Shareholders and potential investors of the company should act carefully when trading or planning to trade the company's securities. In view of the instructions in this announcement, the company plans not to make a separate announcement after the clinical project is officially included in the BTD list.